Federal Register / Vol. 77, No. 40 / Wednesday, February 29, 2012 / Notices 12317 

has been demonstrated to be involved in 

cancer is the Wnt/beta catenin signaling 

pathway. The NIH scientists associated 

with this technology have identified a 

potential new biomarker for cancer 

based on their investigation of the role 

of the secreted frizzled related proteins, 

sFRP’s, which are known to play a role 

in Wnt/beta catenin signaling. In 

particular, the scientists have 

determined that different Frizzled 

receptors (Fzd) have different and 

opposite roles in Wnt/beta catenin 

signaling with the expression of certain 

Fzd receptors, e.g. Fzd5, being 

associated with an increase in Wnt/beta 

catenin signaling and the expression of 

other Fzd receptors, e.g., Fzd2, being 

associated with a decrease in Wnt/beta 

catenin signaling. 

Potential Commercial Applications 

• As a diagnostic to identify patients 

for whom frizzled antagonists may be 

useful therapeutic agents. 

• As an aid for determining the 

appropriate level of frizzled antagonist 

to be given to a patient. 

• As an aid in drug discovery for the 

evaluation of Wnt/frizzled antagonists. 

Competitive Advantages 

• Ability to stratify clinical trials by 

identifying patients whose tumor has 

the appropriate molecular signature. 

• Ability to provide an appropriate 

dosing regimen based on the specificity 

of the drug for a particular Fzd. 

• Tool for further characterizing 

cancer drugs which target the Wnt/beta 

catenin pathway providing for more 

well characterized and specific drugs. 

Development Stage 

• Early-stage. 

• In vitro data available. 

Inventors: Jeffrey S. Rubin, Charles P. 

Xavier, and Maria Melikova (all of NCI). 

Intellectual Property 

• HHS Reference No. E–196–2011/ 

0—U.S. Provisional Application No. 61/ 

497,513 filed 15 Jun 2011. 

• HHS Reference No. E–196–2011/ 

1—U.S. Provisional Application No. 61/ 

499,684 filed 21 Jun 2011. 

Related Technologies: NIH also has 

other intellectual property (IP) related to 

sFRP which may be useful in 

conjunction with the use of the 

biomarker described above. The IP 

includes patents belonging to: 

• HHS Reference No. E–160–1997/ 

2—U.S. Patents 6,479,255 and 

7,183,377. 

• HHS Reference No. E–014–2000/ 

0—U.S. Patents 6,600,018, 7,223,853, 

and 7,947,651. 

• HHS Reference No. E–060–2000/ 

1—U.S. Patent 7,488,710; Foreign patent 

protection is also available (PCT/US02/ 

00869, published as WO 02/055547). 

Licensing Contact: Susan S. Rucker; 

301–435–4478; ruckersu@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Cancer Institute is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate or 

commercialize Regulation of Wnt and 

Frizzled signaling by secreted Frizzledrelated proteins. For collaboration 

opportunities, please contact John 

Hewes, Ph.D. at hewesj@mail.nih.gov. 

A Highly Potent Human sRAGE Protein 

for Treating Vascular Disease, Injury, 

or Inflammation 

Description of Technology: The 

receptor for advanced glycation end 

products (RAGE) is a cell surface 

protein that triggers signaling pathways 

leading to inflammation. RAGEstimulated inflammation can contribute 

to adverse vascular conditions, such as 

atherosclerosis and restenosis. The 

soluble version of RAGE (sRAGE) binds 

the same target molecules (advanced 

glycation end products), but cannot 

activate inflammatory signaling 

pathways. For this reason, sRAGE is 

thought to act as a decoy for RAGE. 

sRAGE reduces inflammation and 

pathogenic consequences associated 

with RAGE signaling. The 

administration of sRAGE has been used 

to treat atherosclerosis and arterial 

restenosis in animal models. The 

inventors established a way to produce 

human sRAGE with more than 1000- 

fold greater potency than current 

methods. Production of full length 

human sRAGE in cultured mammalian 

cells enables addition of mammalian 

post-translational modifications that 

dramatically enhance potency. This 

invention covers methods of 

production, the resulting modified 

sRAGE molecules, and methods of using 

this highly potent sRAGE for treating 

adverse vascular conditions. 

Potential Commercial Applications 

• Atherosclerosis therapeutics. 

• Prevention of vascular 

inflammation. 

• Treating vascular injuries due to 

angioplasty or traumatic injury. 

• Treating vascular complications of 

diabetes mellitus. 

• Alzheimer’s disease treatment 

based on amyloid-beta protein binding. 

Competitive Advantages 

• Greater than 1000-fold increased 

potency over sRAGE produced in insect 

cells. 

• Readily scalable production as a 

recombinant protein secreted from CHO 

cells. 

• Simple affinity purification method. 

Development Stage 

• Early-stage. 

• Pre-clinical. 

• In vitro data available. 

• In vivo data available (animal). 

Inventors: Li Lin, Sungha Park, Wen 

Wei, Rui-ping Xiao, and Mark Talan 

(NIA). 

Publication: Lin L, et al. RAGE 

signaling in inflammation and arterial 

aging. Front Biosci. 2009 Jan 1;14:1403– 

1413. [PMID 19273137]. 

Intellectual Property: HHS Reference 

No. E–165–2011/0—U.S. Provisional 

Application No. 61/582,574 filed 03 Jan 

2012. 

Related Technology: HHS Reference 

No. E–016–2009/0—U.S. Patent 

Application No. 12/652,395 filed 05 Jan 

2010. 

Licensing Contact: Betty B. Tong, 

Ph.D.; 301–594–6565; 

tongb@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Institute on Aging, 

Laboratory of Cardiovascular Science, is 

seeking statements of capability or 

interest from parties interested in 

collaborative research to further 

develop, evaluate, or commercialize 

sRAGE. For collaboration opportunities, 

please contact Vio Conley, M.S. at 

conleyv@mail.nih.gov. 

Dated: February 23, 2012. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 2012–4736 Filed 2–28–12; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 


tkelley on DSK3SPTVN1PROD with NOTICES
12318 Federal Register / Vol. 77, No. 40 / Wednesday, February 29, 2012 / Notices 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Tooth 

Development and Mobility, Mineralized 

Tissue and Periodontal Disease. 

Date: March 16, 2012. 

Time: 11:30 a.m. to 1 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Priscilla B Chen, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4104, 

MSC 7814, Bethesda, MD 20892, (301) 435– 

1787, chenp@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: February 21, 2012. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2012–4743 Filed 2–28–12; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2) notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The purpose of this 

meeting is to evaluate requests for 

development resources for potential 

new cancer diagnostics. The outcome of 

the evaluation will provide information 

for consideration by an internal NCI 

committee that will decide whether 

NCI/DCTD should support requests and 

make available contract resources for 

development of the potential 

diagnostics to improve the treatment of 

cancer. The research proposals and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material and 

personal information concerning 

individuals associated with the 

proposed research projects, the 

disclosure of which would constitute a 

clearly unwarranted invasion of 

personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Clinical 

Assay Development Program (CADP). 

Date: April 10, 2012. 

Time: 8 a.m.–4 p.m. 

Agenda: To evaluate requests for 

development resources for potential new 

diagnostics for cancer. 

Place: National Cancer Institute, NIH, 6001 

Executive Boulevard, Room C, Rockville, MD 

20852. 

Contact Person: Tracy G. Lively, Ph.D., 

Executive Secretary, Clinical Assay 

Development Program (CADP), National 

Cancer Institute, NIH, 6130 Executive 

Boulevard, EPN/6042, Bethesda, MD 20892, 

301–496–1591, livelyt@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: February 22, 2012. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2012–4750 Filed 2–28–12; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; 

Collaborative Research in Integrative Cancer 

Biology and the Tumor Microenvironment. 

Date: March 20, 2012. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda North Marriott Hotel & 

Conference Center, 5701 Marinelli Road, 

Bethesda, MD 20852. 

Contact Person: Eun Ah Cho, Ph.D., 

Scientific Review Officer, Special Review & 

Logistics Branch, Division of Extramural 

Activities, National Cancer Institute, NIH, 

6116 Executive Blvd., Suite 703, Room 7073, 

Bethesda, MD 20892, 301–435–1822, 

choe@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Novel 

Imaging Agents to Expand the Clinical 

Toolkit for Cancer Diagnosis, Staging & 

Treatment. 

Date: March 22, 2012. 

Time: 9 a.m. to 5 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 6116 

Executive Boulevard, Room 706, Bethesda, 

MD 20892 (Telephone Conference Call). 

Contact Person: Ilda M McKenna, Ph.D., 

Scientific Review Officer, Research Training 

Review Branch, Division of Extramural 

Activities, National Cancer Institute, 6116 

Executive Boulevard, Room 8111, Bethesda, 

MD 20892, 301–496–7481, 

mckennai@mail.nih.gov. 

Information is also available on the 

Institute’s/Center’s home page: http:// 

deainfo.nci.nih.gov/advisory/sep/sep.htm, 

where an agenda and any additional 

information for the meeting will be posted 

when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: February 22, 2012. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2012–4752 Filed 2–28–12; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Eye Institute; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 


tkelley on DSK3SPTVN1PROD with NOTICES